Navigating CAR-T cell therapy trials during economic downturns requires strategic approaches to manage costs without compromising quality. Leveraging technology, enhancing training, and optimizing hiring practices can improve operations and potentially advance timelines by utilizing opportunities such as available manufacturing slots. A holistic portfolio assessment ensures informed decision-making, balancing immediate challenges with long-term objectives.
